Bariatric Surgery Versus Diet Alone in the Bile Acid Pathway and Weight Loss

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT03238794
Collaborator
(none)
21
1
2
31.9
0.7

Study Details

Study Description

Brief Summary

It is unknown whether the bile acid pathway reacts differently to weight loss resulting from Roux-En-Y Gastric Bypass (RYGB) surgery than weight loss resulting from caloric restriction alone.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Roux-En-Y Gastric Bypass
  • Other: Low-calorie Diet
N/A

Detailed Description

Participants will be placed into two groups. The Roux-En-Y Gastric Bypass (RYGB) group will consist of participants who will have elected to have RYGB at the Mayo Clinic Bariatric Center of Excellence. The Diet group will have a low-calorie diet prescribed by a registered dietitian. Both groups will collect stool from every bowel movement 2 days before presenting for baseline testing. Both group participants will present for baseline testing after an overnight fast and before intervention (RYGB or low calorie diet). Participants will consume a standard breakfast provided by study staff and blood samples will be collected at -15, 0, 15, 30,45,60,90,120,150,180,210,240,300,360 minutes. Appetite and satiation ratings will be recorded via questionnaires during that day every 15 minutes for the first 90 minutes, then every 30 minutes. Participants will repeat this regimen again after losing 7% of their body weight after having RYGB or low calorie diet.

Study Design

Study Type:
Interventional
Actual Enrollment :
21 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Effect of Weight Loss Through RYGB Versus Weight Loss Through Caloric Restriction on the Bile Acid Pathway
Actual Study Start Date :
May 17, 2019
Actual Primary Completion Date :
Jan 11, 2022
Actual Study Completion Date :
Jan 11, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Roux-En-Y Gastric Bypass (RYGB)

Participants will have elected to have RYGB surgery per standard of care.

Procedure: Roux-En-Y Gastric Bypass
Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
Other Names:
  • RYGB
  • Active Comparator: Low-calorie Diet

    Participants will have a low-calorie diet prescribed by a registered dietitian.

    Other: Low-calorie Diet
    Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.

    Outcome Measures

    Primary Outcome Measures

    1. Change in Bile Acid (BA) excretion [baseline, 12 weeks]

      Total Fecal BA excretion change measured in mcmoles/48 hours

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Women of childbearing potential will have negative pregnancy tests within 48 hours of enrolment.

    • BMI: ≥ 40

    • Individuals who have elected to have RYGB at the Mayo Clinic Bariatric Center of Excellence, and individuals with a BMI ≥40 who are otherwise healthy with controlled cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, or endocrine disorders. The RYGB participants will be invited to participate when their surgery is scheduled at the Mayo Clinic Bariatric Center of Excellence.

    • The non-RYGB participants (BMI ≥40) will be otherwise healthy individuals with no unstable psychiatric disease and no unstable cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, or endocrine disorders.

    Exclusion Criteria:
    • History of abdominal surgery including cholecystectomy and other than appendectomy, Caesarian section or tubal ligation.

    • Positive history of chronic gastrointestinal diseases, or systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., orlistat, phentermine.

    • Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), a self-administered alcoholism screening test (AUDIT-C) and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia). If such a dysfunction is identified by a depression or anxiety score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up. The AUDIT-C is a 3-item alcohol screening questionnaire that reliably identifies participants who are hazardous alcohol drinkers or have active alcohol use disorders. In men, a score of 4 or more is above the recommended limits will be reviewed by study personnel. In women, a score of 3 or more is above the recommended limits will be reviewed by study personnel. However when the points are above recommended limits, the provider will review the patient's alcohol intake over the past few months to confirm accuracy and determine study eligibility.

    • Any acute or chronic condition or other disease that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study.Participant activities:

    • If recruited for the investigation participants will be asked to refrain from donating blood; refrain from participating in other research studies; avoid taking any additional over the counter or prescription medications or herbal supplements that have not been reviewed and approved by the physician or the study coordinator until the study has been completed

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

    Sponsors and Collaborators

    • Mayo Clinic

    Investigators

    • Principal Investigator: Andres J Acosta, MD, Mayo Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Andres J. Acosta, M.D., Ph.D., Principal Investigator, Mayo Clinic
    ClinicalTrials.gov Identifier:
    NCT03238794
    Other Study ID Numbers:
    • 16-008664
    First Posted:
    Aug 3, 2017
    Last Update Posted:
    Jan 24, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Andres J. Acosta, M.D., Ph.D., Principal Investigator, Mayo Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 24, 2022